New Robotic Surgical Systems in Urology: An Update

Theodore Cisu; Fabio Crocerossa; Umberto Carbonara; Francesco Porpiglia; Riccardo Autorino


Curr Opin Urol. 2021;31(1):37-42. 

In This Article


After a 10-year collaborative effort between Korean academic and industry groups, Meerecompany (Hwasong, Korea) received Korean Ministry of Food and Drug Safety approval in 2017 for human work with its Revo-i robotic surgical system ( This is a master--slave system consisting of a surgeon control console and a four-armed system on an operation cart (Supplementary Figure 1, Meerecompany has also developed a virtual reality training system for the system ('revo sim') to allow novice robotic surgeons to improve their psychomotor and instrument handling skills (

Preliminary animal studies using a live porcine model demonstrated the safety and efficacy of the system when used for nephrectomy, fallopian tube surgery, and cholecystectomy.[8–10] The first human study in 2018 demonstrated the safety and efficacy of the Revo-i system in performing a radical prostatectomy using 17 patients, with no serious complications or system failures and relatively comparable operative times compared with those performed on the da Vinci systems.[11] A second human study from investigators at Yonsei university was a single operative experience delineating the technical feasibility of the Revo-i in performing a pancreaticoduodenectomy in a patient with an insulinoma, in which there were no complications[12] (Table 2).